Q2 2016 Outlook Report

April 28, 2016

<img src="https://citeline.com/wp-content/uploads/Outlook-report-banner-1.png" alt="Outlook report banner (1)" class="alignright size-full wp-image-17172" /> <BR><BR> In this report, <strong>we cover catalysts from 21 drugs, devices and diagnostics expected to occur in Q2 2016</strong>. We have also included a list of large Impact catalysts in the drug and device/diagnostic areas through Q2 2016 from our sister product, CatalystTracker. In addition, each drug’s likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. <BR><BR> Our <a href="http://www.biomedtracker.com/ReportDetail.cfm?ReportID=672">Early 2016 Outlook Report</a> highlighted several high- impact catalysts. The results of these catalysts can be found on Page 5 of this report. Biomedtracker Likelihood of Approval (LOA) opinions successfully predicted 78% of catalyst outcomes that occurred in Early 2016. <BR><BR> <strong>To download a complimentary copy of Biomedtrackers & Meddevicetrackers Q2 2016 Outlook report, please use the form to the right.</strong>